Ex Vivo Profiling of CD8+-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers
Top Cited Papers
- 1 May 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (9) , 5226-40
- https://doi.org/10.1128/jvi.77.9.5226-5240.2003
Abstract
Human cytomegalovirus (HCMV) can establish both nonproductive (latent) and productive (lytic) infections. Many of the proteins expressed during these phases of infection could be expected to be targets of the immune response; however, much of our understanding of the CD8+-T-cell response to HCMV is mainly based on the pp65 antigen. Very little is known about T-cell control over other antigens expressed during the different stages of virus infection; this imbalance in our understanding undermines the importance of these antigens in several aspects of HCMV disease pathogenesis. In the present study, an efficient and rapid strategy based on predictive bioinformatics and ex vivo functional T-cell assays was adopted to profile CD8+-T-cell responses to a large panel of HCMV antigens expressed during different phases of replication. These studies revealed that CD8+-T-cell responses to HCMV often contained multiple antigen-specific reactivities, which were not just constrained to the previously identified pp65 or IE-1 antigens. Unexpectedly, a number of viral proteins including structural, early/late antigens and HCMV-encoded immunomodulators (pp28, pp50, gH, gB, US2, US3, US6, and UL18) were also identified as potential targets for HCMV-specific CD8+-T-cell immunity. Based on this extensive analysis, numerous novel HCMV peptide epitopes and their HLA-restricting determinants recognized by these T cells have been defined. These observations contrast with previous findings that viral interference with the antigen-processing pathway during lytic infection would render immediate-early and early/late proteins less immunogenic. This work strongly suggests that successful HCMV-specific immune control in healthy virus carriers is dependent on a strong T-cell response towards a broad repertoire of antigens.Keywords
This publication has 50 references indexed in Scilit:
- Identification of the HLA-A24 Peptide Epitope within Cytomegalovirus Protein pp65 Recognized by CMV-Specific Cytotoxic T LymphocytesViral Immunology, 2001
- Development of a cytomegalovirus vaccine: lessons from recent clinical trialsExpert Opinion on Biological Therapy, 2001
- Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1‐Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1‐Specific CTLsThe Journal of Infectious Diseases, 2000
- ConclusionsAmerican Heart Journal, 1999
- Diastolic potentials in verapamil-sensitive ventricular tachycardia: True potentials or bystanders of the reentry circuits?American Heart Journal, 1999
- Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interactionEuropean Journal of Immunology, 1999
- Guinea pig and human cytomegaloviruses do not share cross‐reactive neutralizing epitopesJournal of Medical Virology, 1995
- The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cellsInternational Immunology, 1994
- Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.The Journal of Experimental Medicine, 1992
- Vaccines for the Prevention of Human Cytomegalovirus InfectionClinical Infectious Diseases, 1990